|
Toll Free: (877) 796-6397 -- USA and Canada only -- |
Fax: +1-832-582-8590 Orders: +1-832-582-8158 |
Tech Support: +1-832-582-8158 Ext:3 Please provide your Order Number in the email. |
Technical Data
| Formula | C13H11BrN2O3 |
|||
| Molecular Weight | 323.14 | CAS No. | 2093387-36-9 | |
| Solubility (25°C)* | In vitro | DMSO | 21 mg/mL (64.98 mM) | |
| Water | Insoluble | |||
| Ethanol | Insoluble | |||
|
* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. * Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.) |
||||
Preparing Stock Solutions
Biological Activity
| Description | Lenalidomide-Br is a brominated analog of lenalidomide, designed for use as a chemical tool in PROTAC research. It serves as a cereblon (CRBN)-recruiting ligand, enabling targeted protein degradation through the CRL4CRBN E3 ubiquitin ligase complex. |
|---|
Protocol (from reference)
References
|
Selleck's Lenalidomide-Br has been cited by 15 publications
| Proteomic profiling reveals CDK6 upregulation as a targetable resistance mechanism for lenalidomide in multiple myeloma [ Nat Commun, 2022, 13(1):1009] | PubMed: 35197447 |
| NEDD4L binds the proteasome and promotes autophagy and bortezomib sensitivity in multiple myeloma [ Cell Death Dis, 2022, 13(3):197] | PubMed: 35236820 |
| SORT1/LAMP2-mediated Extracellular Vesicle Secretion and Cell Adhesion Are Linked to Lenalidomide Resistance in Multiple Myeloma [ Blood Adv, 2022, bloodadvances.2021005772] | PubMed: 34979567 |
| Molecular and functional profiling identifies therapeutically targetable vulnerabilities in plasmablastic lymphoma [ Nat Commun, 2021, 12(1):5183] | PubMed: 34465776 |
| Low NCOR2 levels in multiple myeloma patients drive multidrug resistance via MYC upregulation [ Blood Cancer J, 2021, 11(12):194] | PubMed: 34864816 |
| IRF4 modulates the response to BCR activation in chronic lymphocytic leukemia regulating IKAROS and SYK [ Leukemia, 2021, 35(5):1330-1343] | PubMed: 33623139 |
| Comprehensive CRISPR-Cas9 screens identify genetic determinants of drug responsiveness in multiple myeloma [ Blood Adv, 2021, 5(9):2391-2402] | PubMed: 33950175 |
| IMiDs uniquely synergize with TKIs to upregulate apoptosis of Philadelphia chromosome-positive acute lymphoblastic leukemia cells expressing a dominant-negative IKZF1 isoform [ Cell Death Discov, 2021, 7(1):139] | PubMed: 34117218 |
| Novel Peptide-drug Conjugate Melflufen Efficiently Eradicates Bortezomib-resistant Multiple Myeloma Cells Including Tumor-initiating Myeloma Progenitor Cells [ Hemasphere, 2021, 5(7):e602] | PubMed: 34136753 |
| Fractionated Irradiation of Right Thorax Induces Abscopal Damage on Bone Marrow Cells via TNF-α and SAA [ Int J Mol Sci, 2021, 22(18)9964] | PubMed: 34576128 |
RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.
SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.
NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.